Qynapse (France) and True Positive Medical Devices (Canada) Partner to Provide Most Advanced AI Platform for Brain Disease

0
18


Strategic partnership in brain imaging and AIQYNAPSE SAS, a French medical technology company, announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off of the universities of McGill and Laval. The aim of this strategic collaboration is to combine technologies, patents and expertise of TPMD with the know-how and product line of Qynapse – and thus form the most advanced artificial intelligence (AI) platform. in the field of imaging brain diseases such as Alzheimer’s disease, Parkinson’s disease and multiple sclerosis.

Recommended AI news: ADROSONIC and Riversand Partner to Provide Cloud-Native MDM and PIM Solutions for the Insurance Industry

Over the past fifteen years, the founders of TPMD, Prof. Louis Collins (mcgill university, Montreal, Canada) and Prof. Simon duchesne (University Laval, Quebec, Canada) have established one of the most impressive scientific and technological asset bases in brain imaging and applied AI to this field, supported by more than 500 scientific publications and communications. These technologies are already used in Canada by leading research consortia and international private actors in studies specifically related to neurodegeneration, such as Alzheimer’s disease.

QYNAPSE is already marketing its first QyScore medical device to clinical centers in L’Europe  and United States. Its platform is also used in clinical trials involving dozens of centers around the world. The collaboration with TPMD will allow QYNAPSE to extend the applications of its QyScore software to other brain diseases such as stroke, epilepsy, autism, schizophrenia and head trauma – and also to develop a new software to predict the clinical progression of each patient and optimize recruitment in clinical trials.
The acquisition of TPMD by QYNAPSE covers 15 patents, including 9 issued in United States and Canada, grouped into nine families of technological assets. The founders of TPMD will join the scientific board of QYNAPSE, paving the way for a long-term collaboration.

Recommended AI news: ID Tech Revolutionizes STEM Learning With Fun and Personalized Online Math Lessons

According to Prof. Louis Collins: “QYNAPSE is a very promising partner for TPMD and the two McGill and Laval universities, which will allow us to accelerate the regulatory approval and commercialization of the technologies that we have developed in recent years ”. Professor Duchesne adds: “Indeed, with QYNAPSE, we will have access to a partner already well established in the medical field. We look forward to providing clinicians with the tools they need to improve diagnostic accuracy, aid prognosis, and guide the treatment of conditions such as dementia and cerebrovascular disease.

“We are delighted to partner with two of the world’s leading experts in brain imaging and to expand our scientific and clinical collaborations with two major centers of excellence in this field.” said Olivier Courrèges, CEO of QYNAPSE. “This collaboration will create a unique technological framework, strengthening our ability to deploy powerful tools to address two major challenges: the performance of clinical trials and the personalized management of brain diseases, which affect more than one in six people worldwide.

Recommended AI news: Trust Stamp and OneBanks partner to increase accessibility to secure and reliable banking services

LEAVE A REPLY

Please enter your comment!
Please enter your name here